Alpha 2.0
Login Register
» Articles » PMID: 32292459

Microalbuminuria (Moderate Albumin Excretion) and Its Relationship with Silent Myocardial Ischemia in Treatment Naïve Type II Diabetic Patients

Overview
Journal Pak J Med Sci
Specialty General Medicine
Date 2020 Apr 16
PMID 32292459
Authors
Qurban Hussain
Mulazim Hussain Bukhari
Faiza Afzaal
Wajiha Fatima
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the frequency of microalbuminuria (MAU) or Moderate Albumin Excretion (MAE) in treatment naïve type II diabetic patients and to compare the frequency of silent myocardial ischemia in treatment naive Type-II diabetic patients with and without microalbuminuria.

Methods: It was a cross sectional survey conducted in the outpatient Department, Jinnah Hospital Lahore, from 30th May 2015 to 29th November 2015. There were 227 patients, (consecutive treatment naïve type II diabetic patients), presenting to outpatient department were enrolled in the study. MAU/MAE, silent myocardial ischemia and effect modifiers like HbA1C > 7%, smoking pack years and dyslipidemia was determined. MAU/MAE was determined by urinary albumin excretion rate of 30-300 mg/24 hours and included patients underwent exercise tolerance test to diagnose silent myocardial ischemia.

Results: Out of total 165 patients (72.7%) were male and remaining 62 patients (27.3%) were female. The 54 patients (23.8%) had MAU/MAE. The 44 patients (19.4%) had silent myocardial infarction. When we cross tabulated microalbuminuria with silent myocardial infarction, result were significant. Out of 54 patients with MAU/MAE, 16 cases had silent myocardial infarction.

Conclusion: The frequency of microalbuminuria/ Moderate Albumin Excretion in treatment naïve type II diabetic patients was high and associated with the frequency of silent myocardial ischemia in treatment naïve type II diabetic patients with and without MAU MAU/MAE.

References
1.
Nadir M, Rekhraj S, Wei L, Lim T, Davidson J, MacDonald T . Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012; 60(11):960-8. DOI: 10.1016/j.jacc.2012.04.049. View
2.
Marciano C, Galderisi M, Gargiulo P, Acampa W, DAmore C, Esposito R . Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. Eur J Nucl Med Mol Imaging. 2012; 39(7):1199-206. DOI: 10.1007/s00259-012-2117-9. View
3.
Swoboda P, McDiarmid A, Erhayiem B, Ripley D, Dobson L, Garg P . Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. J Am Heart Assoc. 2017; 6(7). PMC: 5586286. DOI: 10.1161/JAHA.117.005539. View
4.
Bourque J, Patel C, Ali M, Perez M, Watson D, Beller G . Prevalence and predictors of ischemia and outcomes in outpatients with diabetes mellitus referred for single-photon emission computed tomography myocardial perfusion imaging. Circ Cardiovasc Imaging. 2013; 6(3):466-77. PMC: 3774120. DOI: 10.1161/CIRCIMAGING.112.000259. View
5.
de Boer I, Rue T, Cleary P, Lachin J, Molitch M, Steffes M . Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011; 171(5):412-20. PMC: 3085024. DOI: 10.1001/archinternmed.2011.16. View